JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: Medical Writing

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: The SENTRY Surveillance Program in Europe 2000.

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: The SENTRY Surveillance Program in Europe 2000. by Rodriguez-Villalobos H, Jones RN, Struelens MJ published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):196-197

Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 1997-2000. Abstr. #P456

Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 1997-2000. Abstr. #P456 by Canton R, Loza E, Morosini MI, Voerhoef J and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):75

Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli.

Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli. by Howard W, Biedenbach DJ, Jones RN published in Clin. Microbiol. Infect. 2002; 8: 340-344

Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.

Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. by Nicholson SC, Naughton BJ, Webb CD. published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 117-125

Re-evaluations of disk diffusion quality control ranges for 11 drugs: Report from the QC working group of the national committee for Clinical Laboratory Standards.

Re-evaluations of disk diffusion quality control ranges for 11 drugs: Report from the QC working group of the national committee for Clinical Laboratory Standards. by Jones RN, Cullen S and NCCLS Quality Control Working Group Participants published in Int. J. Antimicrob. Agents 2002; 20 (4): 289-292

Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.

Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. by Nicholson SC, High KP, Gothelf S and Webb CD published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 109-116

Fluoroquinolones for the treatment of outpatient community-acquired pneumonia.

Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. by Jones RN and Mandell LA published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 69-76

Oral gatifloxacin in outpatient community-acquired pneumonia: Results from TeqCES, a community-based, open-label, multicenter study.

Oral gatifloxacin in outpatient community-acquired pneumonia: Results from TeqCES, a community-based, open-label, multicenter study. by Gotfried M, Quinn T, Gothelf S, Wikler MA, Webb CD and Nicholson SC. published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 85-91

Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.

Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. by Jones RN, Andes DR, Mandell LA, Gothelf S, Ehrhardt AF and Nicholson SC published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 93-100

First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan.

First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan. by Yu WL, Winokur PL, Von Stein DL, Pfaller MA, Wang JH and Jones RN published in Antimicrob Agents Chemother 2002; 46 (4): 1098-1100

Implications of TeqCES: Efficacy and safety of gatifloxacin in community-acquired pneumonia.

Implications of TeqCES: Efficacy and safety of gatifloxacin in community-acquired pneumonia. by Mandell LA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 127-128

Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.

Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. by Yu WL, Pfaller MA, Winokur PL and Jones RN published in Emerg. Infect. Dis. 2002; 8 (5): 522-524

Haemophilus influenzae in respiratory tract infections in community-based clinical practice: Therapy with gatifloxacin.

Haemophilus influenzae in respiratory tract infections in community-based clinical practice: Therapy with gatifloxacin. by Nicholson SC, Webb CD, Andriole VT, Jones RN and Wilson WR published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 101-107

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species.

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. by Jones RN, Biedenbach DJ and Anderegg TR published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 119-122

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. by Jones RN, Anderegg TR and Deshpande LM published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 87-90

Pharmacodynamics in the evaluation of drug regimens.

Pharmacodynamics in the evaluation of drug regimens. by Bhavnani SM, Ambrose PG and Jones RN published in Ann. Pharmacother. 2002; 36 (3): 530-532

A multicentre evaluation of linezolid antimicrobial activity in North America.

A multicentre evaluation of linezolid antimicrobial activity in North America. by Ballow CH, Jones RN, Biedenbach DJ and North American ZAPS Research Group published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 75-83

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. by Ambrose PG, Owens RC, Jr., Garvey MJ, and Jones RN published in J. Antimicrob. Chemother. 2002; 49 (3): 445-453

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. by Johnson DM, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 49-60

Quality control guidelines for tiamulin (DenagardTM) susceptibility testing.

Quality control guidelines for tiamulin (DenagardTM) susceptibility testing. by Walter D, Pfaller MA and Jones RN published in Proceedings of the 17th IPVS Congress, Ames, IA June 2-5, 2002; Vol 2: 256

A cost-benefit analysis of RSV prophylaxis in high risk infants.

A cost-benefit analysis of RSV prophylaxis in high risk infants. by Schrand L, Elliott J, Ross M, Bell E and Mutnick A published in Ann. Pharmacother. 2001; 35 (10): 1186-1193

Resistance patterns among nosocomial pathogens: Trends over the past few years.

Resistance patterns among nosocomial pathogens: Trends over the past few years. by Jones RN published in Chest 2001; 119 (Suppl 2): 397S-404S

Evaluation of antimicrobial surgical prophylaxis with multiattribute utility theory.

Evaluation of antimicrobial surgical prophylaxis with multiattribute utility theory. by Smith TA, Behm Dillon DM and Mutnick AH published in Am. J. Health. Syst. Pharm. 2001; 58 (3): 251-255

Activity and spectrum of BMS 284756, a new des-F(6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

Activity and spectrum of BMS 284756, a new des-F(6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. by Jones RN, Pfaller MA and Stilwell M published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 133-135

Comparison of the Vitek Gram-positive susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus.

Comparison of the Vitek Gram-positive susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus. by Yamazumi T, Marshall SA, Wilke WW, Diekema DJ, Pfaller MA and Jones RN published in J. Clin. Microbiol. 2001; 39 (1): 53-56

Conventional dogma applied to quinolones? Time for a change.

Conventional dogma applied to quinolones? Time for a change. by Jones RN published in J. Antimicrob. Chemother. 2001; 47 (6): 893

Comparison of the Vitek Gram-positive susceptibility 106 card, the MRSA-Screen latex agglutination test, and mec A analysis for detecting oxacillin resistance in a geographically diverse collection of clinical isolates of coagulase-negative staphylococci.

Comparison of the Vitek Gram-positive susceptibility 106 card, the MRSA-Screen latex agglutination test, and mec A analysis for detecting oxacillin resistance in a geographically diverse collection of clinical isolates of coagulase-negative staphylococci. by Yamazumi T, Furuta I, Diekema DJ, Pfaller MA and Jones RN published in J. Clin. Microbiol. 2001; 39 (10): 3633-3636

Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001).

Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001). by Jones RN and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2001; 40 (1-2): 71-73

Characterization of extended spectrum β-lactamase-producing Klebsiella pneumoniae from Beijing, China.

Characterization of extended spectrum β-lactamase-producing Klebsiella pneumoniae from Beijing, China. by Shen D, Winokur P and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (2): 185-188

Method preferences and test accuracy of antimicrobial susceptibility testing: Updates from the College of American Pathologists Microbiology Surveys Program.

Method preferences and test accuracy of antimicrobial susceptibility testing: Updates from the College of American Pathologists Microbiology Surveys Program. by Jones RN published in Arch. Pathol. Lab. Med. 2001; 125: 1285-1289

Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.

Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae. by Rospide MF, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents. 2001; 17 (6): 451-455

Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: More evidence for a class concept.

Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: More evidence for a class concept. by Jones RN published in J. Clin. Microbiol. 2001; 39 (10): 3810-3811

Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.

Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. by Rhomberg PR, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 40 (1-2): 45-49

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) closing summary. Hamburg, Germany, 10 May 2001.

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) closing summary. Hamburg, Germany, 10 May 2001. by Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 197-198

Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.

Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America. by Pfaller MA and Jones RN published in J. Clin. Microbiol. 2001; 39 (7): 2748-2750

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines.

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. by Gales AC, Reis AO and Jones RN published in J. Clin. Microbiol. 2001; 39 (1): 183-190

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons, abstr P37.

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons, abstr P37. by Pfaller MA, Jones RN, Biedenbach DJ and Beach ML published in J Antimicrob Chemother 2001; 47 (Suppl S1): 26

Oxazolidinone antibiotics.

Oxazolidinone antibiotics. by Diekema DJ and Jones RN published in Lancet 2001; 358 (9297): 1975-1982

Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin.

Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin. by Pfaller MA, Jones RN and Walter DH published in Diagn. Microbiol. Infect. Dis. 2001; 40 (1-2): 67-70

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods. by Deshpande L, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (5): 437-440

Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. by Pfaller MA, Messer SA, Mills K, Bolmstrom A and Jones RN. published in J. Clin. Microbiol. 2001; 39 (11): 3952-3954

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 257-260

Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.

Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. by Pfaller MA, Messer SA, Mills K, Bolmstrom A and Jones RN published in J. Clin. Microbiol. 2001; 39 (12): 4387-4389

Assessment of BMS284756 MIC and 5-µg disk diffusion quality control studies tested against seven American type culture collection strains.

Assessment of BMS284756 MIC and 5-µg disk diffusion quality control studies tested against seven American type culture collection strains. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 225-228

Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: Quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole.

Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: Quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole. by McDermott PF, Barry AL, Jones RN, Stein GE, Thornsberry C, Wu CC and Walker RD published in J. Clin. Microbiol. 2001; 39 (12): 4283-4287

Geographic variations in BMS284756 activity against pathogens associated with skin and soft tissue Infections: Report from the SENTRY Antimicrobial Surveillance Program (2000), Abstr P35.

Geographic variations in BMS284756 activity against pathogens associated with skin and soft tissue Infections: Report from the SENTRY Antimicrobial Surveillance Program (2000). Abstr. P35. by Kirby JT, Biedenbach DJ, Pfaller MA, Jones RN, and SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 2): 25

Discussion.

Discussion. by Niederman MS. published in Am. J. Med. 2001; 111 (9 Suppl 1): 36S-38S

Activity of BMS284756 tested against 3,546 strains of ciprofloxacin-resistant Gram-positive cocci. Abstr P45.

Activity of BMS284756 tested against 3,546 strains of ciprofloxacin-resistant Gram-positive cocci. Abstr P45. by Jones RN published in J. Antimicrob. Chemother. 2001; 47(Suppl 1): 28

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. by Nicholau DP and Ambrose PG published in Am. J. Med. 2001; 111 (Suppl 9A): 13S-18S; discussion 36S-38S

Comparative activity of gatifloxacin against S. pneumoniae, H. influenzae, and M. catarrhalis before (1997-99) and during (2000) the clinical release in North America (NA): A SENTRY Antimicrobial Surveillance Program Report, abstr P7.

Comparative activity of gatifloxacin against S. pneumoniae, H. influenzae, and M. catarrhalis before (1997-99) and during (2000) the clinical release in North America (NA): A SENTRY Antimicrobial Surveillance Program Report, abstr P7. by Jones RN, Pfaller MA, and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl S2): 18